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In 1995, during my first week as a neurology resident at
Massachusetts General Hospital, I had the privilege of
meeting the late Raymond Adams. He was an established
octogenarian by then, but the years had made no difference
to his air of professionalism and academic authority. His
reputation was made in the 1950s and 1960s, when he
developed Boston as a major centre of clinical neurology.
Among other things, he is immortalized through a famous
textbook that has appeared in multiple editions.
Our meeting took place at a clinical conference in which
I was required to present a case. He was a demanding
clinician, and my neurological examination did not meet his
standards of thoroughness. Despite my best efforts, I could
not remove the look of displeasure from his face. I defended
myself, invoking time efficiency and what not, but Dr
Adams was unforgiving. ‘You can’t rush a neurological
examination,’ he said. ‘A proper one takes three days.’
Dr Adams was, of course, echoing a mindset that goes
back to the very foundations of neurology. In 1875, Jean-
Martin Charcot had delivered a series of lectures to the
Paris Medical School on cerebral localization, laying out a
method that sought clinical alliance between pathological
cerebral lesions and clinical signs in living patients. He was
already much more than a professor by then, his profile and
personality was compared to Napoleon and Caesar. He was
also well into a legendary career at the Salpeˆtrie`re Hospital
that would enshrine him as the father of neurology.
The method of cerebral lesion localization became the
founding pillar of neurology as a clinical discipline. It is a
powerful diagnostic tool that permits reasonably accurate
spatial localization of a lesion within the nervous system
without resort to technology. The benefits are obvious. The
problem, unfortunately, is that lesion localization became
an end in itself.
It is the element of theatre. A well-conducted
localization exercise enables a formidable display of
clinicoanatomic mental gymnastics that can leave impres-
sionable medical students and trainees gasping. In no other
specialty are clinical examinations performed in front of
large audiences. They are called ‘demonstrations’, but to an
external observer they have all the elements of a freak
show. It is also a very visible activity that creates an
impression that its practitioners are involved in very busy
and important work. Burdened by these distractions, the
line connecting lesion localization to patient therapeutics
and functional outcomes became obscured.
Admittedly, the deck was always stacked against
neurologists. The brain is a complex organ that is slow to
yield its secrets, and without the benefit of imaging
technology the clinical process does not get very far. But
certainly neurologists did themselves no favours when they
got seduced by lesion localization and pursued it for its own
sake.
It was the advent of CT and MR scanning that finally
liberated neurology from these shackles. Indeed, in the
early days of brain imaging, it was commonly said that now
that neurologists can see the lesion on a scan, they would
have nothing to do. It was a joke—but only just. Such was
the hold of lesion localization on the practice of neurology
and on the perceptions it had created among professionals
from other disciplines.
Modern neurology, thankfully, has finally emerged from
this distracting influence. Over the last three decades,
efficacious treatments have become available for the
majority of neurological diseases, including epilepsy,
migraine, Guillain–Barre´ syndrome, Parkinson’s disease,
multiple sclerosis, and ischaemic stroke. This revolution
came about by keeping clinical outcomes foremost through
the integrated application of basic research, drug develop-
ment, biotechnology and clinical trial methodology.
And what about the extended neurological examination?
With the availability of tissue-plasminogen activator as
thrombolytic therapy for acute ischaemic stroke, even 3
minutes is a luxury, let alone 3 days.
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